Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
This is actually really promising. Their approach is currently the safest with the most clinical data behind it (across all their current treatments), especially when you see headlines like this:

https://endpts.com/derailed-gene-therapy-study-reports-3rd-d...

"A third patient has died in Audentes’ pivotal gene therapy trial for X-linked myotubular myopathy, adding fresh concerns for the field right on the heels of BioMarin’s surprise slapdown at the FDA.

The biotech, bought out by Astellas just 8 months ago for $3 billion, says the third patient died from gastrointestinal bleeding. And like the two others who died, this person was on the high dose."

I had peaked at Audentes but decided it was still too early, then they got bought out. AAV appears to have significant strings attached that lentiviral vectors / Bluebirds approach does not. Bluebird seems to still be firing on all cylinders, moving forward ide-cel for multiple myeloma, CALD seems to be approved within a year in US & EU, Zynteglo approved, etc.

btw, editas has started treatment in a whole 3 patients thusfar. ::eyeroll emoji::
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.